Exenatide: international reports of pancreatic cancer

The latest issue of the Canadian Adverse Reaction Newsletter, a quarterly publication that alerts health professionals to potential signals detected through the review of case reports submitted to Health Canada, includes a section on exenatide, a therapy for the management of type 2 diabetes mellitus. Scientific literature raises concerns that exenatide may be associated with an increased risk of pancreatic cancer, but there is limited evidence to date. Read more here.